(Q42997222)

12 November 2017

title

Long-term evolution of serum and liver viral markers in patients treated for chronic hepatitis C and sustained response (English)

1 reference

12 November 2017

1 reference

Moreno M

1

1 reference

12 November 2017

Pérez-Alvarez R

2

1 reference

12 November 2017

Rodrigo L

3

1 reference

12 November 2017

Pérez-López R

4

1 reference

12 November 2017

Suárez-Leiva P

5

1 reference

12 November 2017

language of work or name

1 reference

1 January 2006

1 reference

Journal of Viral Hepatitis

12 November 2017

published in

1 reference

12 November 2017

volume

13

1 reference

12 November 2017

issue

1

1 reference

12 November 2017

page(s)

28-33

1 reference

Viral load and clinicopathological features of chronic hepatitis C (1b) in a homogeneous patient population

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Mucosal immunity and primary biliary cirrhosis: presence of antimitochondrial antibodies in urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Detection of HCV core antigen in human serum and plasma with an automated chemiluminescent immunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Application of a new enzyme-linked immunosorbent assay for detection of total hepatitis C virus core antigen in blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Performance of an automated system for quantitation of hepatitis C virus core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Detection of hepatitis C core antigen in the antibody negative 'window' phase of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Combination HCV core antigen and antibody assay on a fully automated chemiluminescence analyzer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

HCV core antigen as an alternative to NAT to detect HCV viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Evaluation of a total hepatitis C virus (HCV) core antigen assay for the detection of antigenaemia in anti-HCV positive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: a collaborative study between Japan, Egypt, and Uzbekistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Monitoring Response to Antiviral Therapy for Patients with Chronic Hepatitis C Virus Infection by a Core-Antigen Assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Comparative Evaluation of the Total Hepatitis C Virus Core Antigen, Branched-DNA, and Amplicor Monitor Assays in Determining Viremia for Patients with Chronic Hepatitis C during Interferon Plus Ribavirin Combination Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

A new HCV core antigen assay based on disassociation of immune complexes: an alternative to molecular biology in the diagnosis of early HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Comparative study of conventional and novel strategies for the detection of hepatitis C virus RNA in serum: amplicor, branched-DNA, NASBA and in-house PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

The kinetics of antibodies against hepatitis C virus may predict viral clearance in exposed hemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00650.X

10.1111/J.1365-2893.2005.00650.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference